Core Viewpoint - The company Yiming Anke-B (01541) has received approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tida-paisip) for the treatment of atherosclerosis, which has positively impacted its stock price [1] Group 1: Company Developments - Yiming Anke-B's stock price rose over 10% in early trading, currently up 8.63% at HKD 6.67, with a trading volume of HKD 11.1965 million [1] - The company holds global intellectual property and commercialization rights for IMM01 (Tida-paisip) and has a patent family that includes authorized patents in China, the United States, Japan, and the European Union [1] Group 2: Research and Development Insights - Guoyuan International reported that the company has regained global rights for IMM2510 and IMM27M, which will accelerate the pace of global development [1] - Clinical data for IMM2510 is reported to be excellent with good safety and significant differentiation advantages [1] - The company’s R&D pipeline is expanding, enhancing its risk resistance, with promising clinical efficacy data for the CD47CD20 dual antibody (IMM0306), which is expected to become a major drug in the autoimmune field [1] Group 3: Market Valuation - The company is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology, autoimmune diseases, and cardiovascular fields [1] - Currently, the market capitalization is only HKD 2.7 billion, indicating a significant undervaluation, and it is recommended to pay close attention to the company [1]
宜明昂科-B早盘涨超10% IMM01获批进行动脉粥样硬化治疗的临床试验